Furthermore, a 0.15 overall survival probability was identified for patients with high CD86 gene expression in tumor specimens vs. 0.3 for low expression, and 0.25 vs. 0.17 correspondingly in patients with high and low Arg1 gene expression in tumors. Here, CD86 is linked to neoplasm.